{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:32Z","timestamp":1787020232148,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770211"],"award-info":[{"award-number":["81770211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700145"],"award-info":[{"award-number":["81700145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) is a spectrum of disease comprising more than 30% of non-Hodgkin lymphomas. Although studies have identified several molecular subgroups, the heterogeneous genetic background of DLBCL remains ambiguous. In this study we aimed to develop a novel approach and to provide a distinctive classification system to unravel its molecular features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cohort of 342 patient samples diagnosed with DLBCL in our hospital were retrospectively enrolled in this study. A total of 46 genes were included in next-generation sequencing panel. Non-mutually exclusive genetic signatures for the factorization of complex genomic patterns were generated by random forest algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of four non-mutually exclusive signatures were generated, including those with\n                      <jats:italic>MYC<\/jats:italic>\n                      -translocation (\n                      <jats:italic>MYC<\/jats:italic>\n                      -trans) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200962), with\n                      <jats:italic>BCL2<\/jats:italic>\n                      -translocation (\n                      <jats:italic>BCL2<\/jats:italic>\n                      -trans) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200969), with\n                      <jats:italic>BCL6<\/jats:italic>\n                      -translocation (\n                      <jats:italic>BCL6<\/jats:italic>\n                      -trans) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u2009108), and those with\n                      <jats:italic>MYD88<\/jats:italic>\n                      and\/or\n                      <jats:italic>CD79B<\/jats:italic>\n                      mutations (MC) signatures (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u2009115). Comparison analysis between our model and traditional mutually exclusive Schmitz\u2019s model demonstrated consistent classification pattern. And prognostic heterogeneity existed within EZB subgroup of de novo DLBCL patients. As for prognostic impact,\n                      <jats:italic>MYC<\/jats:italic>\n                      -trans signature was an independent unfavorable prognostic factor. Furthermore, tumors carrying three different signature markers exhibited significantly inferior prognoses compared with their counterparts with no genetic signature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with traditional mutually exclusive molecular sub-classification, non-mutually exclusive genetic fingerprint model generated from our study provided novel insight into not only the complex genetic features, but also the prognostic heterogeneity of DLBCL patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07198-1","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T06:03:45Z","timestamp":1596175425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2019 Qi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke\u2019 Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei\u2019 Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao\u2019 Dong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia\u2019 Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2019 Hong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken He","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2019 Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"7198_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood."},{"key":"7198_CR2","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","volume":"26","author":"B Coiffier","year":"2007","unstructured":"Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603\u201313.","journal-title":"Oncogene."},{"key":"7198_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017;171:481\u2013494.e15.","journal-title":"Cell"},{"key":"7198_CR4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"7198_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"7198_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature."},{"key":"7198_CR7","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","volume":"18","author":"A Gonzalez-Aguilar","year":"2012","unstructured":"Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18:5203\u201311.","journal-title":"Clin Cancer Res"},{"key":"7198_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.2019001126","volume":"134","author":"A Mottok","year":"2019","unstructured":"Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019;134:802\u201313.","journal-title":"Blood."},{"key":"7198_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/jid.2013.265","volume":"134","author":"L Koens","year":"2014","unstructured":"Koens L, Zoutman WH, Ngarmlertsirichai P, Przybylski GK, Grabarczyk P, Vermeer MH, et al. Nuclear factor-kappaB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Investigative Dermatol. 2014;134:290\u20132.","journal-title":"J Investigative Dermatol"},{"key":"7198_CR10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2017-02-767335","volume":"130","author":"A Bouska","year":"2017","unstructured":"Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, et al. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood. 2017;130:1819\u201331.","journal-title":"Blood."},{"key":"7198_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:190\u2013201.","journal-title":"J Clin Oncol"},{"key":"7198_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","volume":"37","author":"C Sha","year":"2019","unstructured":"Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, et al. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37:202\u201312.","journal-title":"J Clin Oncol"},{"key":"7198_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood."},{"key":"7198_CR14","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-10-2573","volume":"17","author":"LM Rimsza","year":"2011","unstructured":"Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res. 2011;17:3727\u201332.","journal-title":"Clin Cancer Res"},{"key":"7198_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/bjs.18004921319","volume":"49","author":"IM DAWSON","year":"1961","unstructured":"DAWSON IM, CORNES JS, MORSON BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961;49:80\u20139.","journal-title":"Br J Surg"},{"key":"7198_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"7198_CR17","first-page":"4771","volume":"33","author":"N Gebauer","year":"2013","unstructured":"Gebauer N, Bernard V, Feller AC, Merz H. ID3 mutations are recurrent events in double-hit B-cell lymphomas. Anticancer Res. 2013;33:4771\u20138.","journal-title":"Anticancer Res"},{"key":"7198_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","volume":"134","author":"RI Panea","year":"2019","unstructured":"Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134:1598\u2013607.","journal-title":"Blood."},{"key":"7198_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ng.3473","volume":"48","author":"J Okosun","year":"2016","unstructured":"Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48:183\u20138.","journal-title":"Nat Genet"},{"key":"7198_CR20","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/leu.2014.330","volume":"29","author":"A Clipson","year":"2015","unstructured":"Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29:1177\u201385.","journal-title":"Leukemia."},{"key":"7198_CR21","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.","journal-title":"Nucleic Acids Res"},{"key":"7198_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.18632\/oncotarget.653","volume":"3","author":"AH Khodabakhshi","year":"2012","unstructured":"Khodabakhshi AH, Morin RD, Fejes AP, Mungall AJ, Mungall KL, Bolger-Munro M, et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3:1308\u201319.","journal-title":"Oncotarget."},{"key":"7198_CR23","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1182\/blood-2013-12-546309","volume":"124","author":"NFCC de Miranda","year":"2014","unstructured":"de Miranda NFCC, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014;124:2544\u201353.","journal-title":"Blood."},{"key":"7198_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2017.251","volume":"32","author":"K Karube","year":"2018","unstructured":"Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675\u201384.","journal-title":"Leukemia."},{"key":"7198_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101\u20135.","journal-title":"Nature."},{"key":"7198_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"F Jardin","year":"2016","unstructured":"Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol. 2016;91:923\u201330.","journal-title":"Am J Hematol"},{"key":"7198_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116\u201320.","journal-title":"Nature."},{"key":"7198_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321\u20135.","journal-title":"Nat Genet"},{"key":"7198_CR29","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41467-019-08578-3","volume":"10","author":"C Lopez","year":"2019","unstructured":"Lopez C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hubschmann D, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun. 2019;10:1459.","journal-title":"Nat Commun"},{"key":"7198_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129:473\u201383.","journal-title":"Blood."},{"key":"7198_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1084\/jem.20120904","volume":"209","author":"D Rossi","year":"2012","unstructured":"Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209:1537\u201351.","journal-title":"J Exp Med"},{"key":"7198_CR32","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","volume":"128","author":"V Spina","year":"2016","unstructured":"Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, et al. The genetics of nodal marginal zone lymphoma. Blood. 2016;128:1362\u201373.","journal-title":"Blood."},{"key":"7198_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/8767","volume":"22","author":"Q Zhang","year":"1999","unstructured":"Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t (1;14)(p22;q32). Nat Genet. 1999;22:63\u20138.","journal-title":"Nat Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07198-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07198-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07198-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T19:35:42Z","timestamp":1627673742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07198-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7198"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07198-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Tongji Hospital. All patients have known the details of our project and signed an Informed Consent Form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors in this article declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"714"}}